Aim: The aim of the study was to define the utility of restage TURBT and to evaluate the impact of restage TURBT on the incidence of tumour recurrence and progression in patients with non-muscle invasive bladder cancer. Materials and Methods: A prospective observational study was performed with an aim of analyzing the utility of restage TURBT at a tertiary care centre during July 2018-December 2019. Patients enrolled for restage TURBT were proven with histological diagnosis of non muscle invasive bladder cancer. All patients underwent restage TURBT within 4 to 6 weeks after the initial resection. Comparison of histological findings of initial TURBT and restage TURBT were done. Results:Total data available for 68 patients. Among them 27 patients (40%) were detected to have residual disease. Out of this in 11 patients (40%) high grade tumour residual disease was established and in 14 patients (52%) low grade tumour residual disease was established .Two patients (8%) were detected to have muscle invasive bladder cancer after restage TURBT. Conclusion:The study concluded that the restage TURBT is of clinical significance in non-muscle invasive bladder cancer as it helps in early detection, treatment and prognosis in cases of advanced bladder cancer.

Keywords: Restage TURBT; NMIBC; Residual bladder tumour.